Predict your next investment

Venture Capital
baytechventurecapital.de

See what CB Insights has to offer

Investments

28

Portfolio Exits

5

About BayTech Venture Capital

BayTech Venture Capital is a European Venture Capital firm with the ambition to help the best entrepreneurs build the most successful companies in their fields of expertise.BayTech invests at an early stage in start-up companies in the sectors Technology and Life Sciences in Western Europe, especially in Germany and France.

BayTech Venture Capital Headquarters Location

Ottostr. 21

Munich, D-80333,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest BayTech Venture Capital News

German life sciences firm Pieris pulls in 6.6 mln euros

Nov 26, 2014

November 26, 2014     0 Comments Munich-based life sciences company Pieris AG has raised 6.6 million euros in funding. The investors included Ally Bridge Group, OrbiMed, The Global Life Science Ventures, BioM Venture Capital, Gilde Europe Food & Agribusiness Fund and BayTech Venture Capital. Morrison & Foerster represented Ally Bridge Group in the transaction. PRESS RELEASE BERLIN/HONG KONG (November 26, 2014) – The international law firm Morrison & Foerster (MoFo) represented Ally Bridge Group in its first venture capital investment in Germany. The funding was provided for the fifth financing round of life sciences company Pieris AG, Munich, amounting to EUR 6.6 million in total. Other investors include premier life sciences venture capital investors OrbiMed, The Global Life Science Ventures, BioM Venture Capital, Gilde Europe Food & Agribusiness Fund, and BayTech Venture Capital. Ally Bridge Group (ABG) is a global healthcare-focused investment group, based in Hong Kong and the United States. ABG and its affiliates manage over USD 500 million in assets in the United States, China and Europe with a focus on disruptive technology platforms in both biopharmaceuticals and medical devices. The MoFo corporate team was led by Hong Kong partner Thomas Chou, Berlin partner Dirk Besse and senior associate Robin Eyben. Berlin counsel Sebastian Kost and Hong Kong associate Matthew Lau provided assistance on tax aspects of the deal. Pieris AG is a clinical-stage biotechnology stock corporation based in Munich, Germany, that exploits its propriatory Anticalin technology developing differentiated drugs to help patients suffering from cancer, severe asthma, anemia and other medical conditions. ABOUT MORRISON & FOERSTER We are Morrison & Foerster — a global firm of exceptional credentials. Our clients include some of the largest financial institutions, investment banks, and Fortune 100, technology, and life sciences companies. We’ve been included on The American Lawyer’s A-List for 11 straight years, and the Financial Times named the firm number six on its 2013 list of the 40 most innovative firms in the United States. Our lawyers are committed to achieving innovative and business-minded results for our clients, while preserving the differences that make us stronger. Leave a Reply

BayTech Venture Capital Investments

28 Investments

BayTech Venture Capital has made 28 investments. Their latest investment was in PandoLogic as part of their Series B on November 11, 2010.

CBI Logo

BayTech Venture Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/16/2010

Series B

PandoLogic

$4.7M

No

1

12/11/2009

Series D

EnOcean

$12M

No

1

8/20/2009

Series B - II

Ubidyne

$14.4M

No

1

7/11/2009

Series C

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2008

Series A

Subscribe to see more

$99M

Subscribe to see more

0

Date

11/16/2010

12/11/2009

8/20/2009

7/11/2009

12/19/2008

Round

Series B

Series D

Series B - II

Series C

Series A

Company

PandoLogic

EnOcean

Ubidyne

Subscribe to see more

Subscribe to see more

Amount

$4.7M

$12M

$14.4M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

0

BayTech Venture Capital Portfolio Exits

5 Portfolio Exits

BayTech Venture Capital has 5 portfolio exits. Their latest portfolio exit was PandoLogic on July 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/22/2021

Acquired

$99M

5

12/18/2014

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

1/11/2012

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

8/18/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/6/2005

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

7/22/2021

12/18/2014

1/11/2012

8/18/2011

6/6/2005

Exit

Acquired

Reverse Merger

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

0

10

0

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.